Basal Cell Carcinoma

1. Disease Information

1.1 Definition and current understanding

BCC is described in recent guidelines and reviews as a slow-growing, locally aggressive cutaneous neoplasm arising from the basal layer of the epidermis, with rare metastasis. (lang2024s2kguidelinebasal pages 1-2, schmults2023basalcellskin pages 2-4, sol2024therapeuticapproachesfor pages 7-8)

1.2 Key identifiers and classifications

Because many registries do not systematically record BCC, identifiers are often used indirectly in observational and genetic studies.

• ICD-10 (commonly used for EHR/claims phenotyping): A large 2024 GWAS meta-analysis defined BCC cases in one cohort using ICD-10 codes C44.01–C44.91. (choquet2024multiancestrygenomewidemetaanalysis pages 7-7)
• ICD-O-3 topography (registry-based definition): Japan’s National Cancer Registry analysis defined skin cancers using ICD-O-3 topography codes including C44 (skin) (and additional genital skin topographies), with in situ lesions included. (ogata2023epidemiologyofskin pages 1-2)
• MeSH / MONDO / ICD-11: Not extractable from the retrieved full-text evidence in this run; therefore not asserted here.

1.3 Common synonyms / alternative names

• Basal cell carcinoma of the skin
• Basal cell skin cancer (NCCN nomenclature) (schmults2023basalcellskin pages 2-4)
• Keratinocyte cancer / keratinocyte carcinoma (umbrella term often including BCC and cSCC) (vallini2023signalingpathwaysand pages 1-2, yang2023trendsinkeratinocyte pages 1-8)

1.4 Evidence sources (patient-level vs aggregated)

• Aggregated resources/guidelines: NCCN Clinical Practice Guideline (Version 2.2024; published 2023) and German S2k guideline update 2023 (published 2024). (schmults2023basalcellskin pages 2-4, lang2024s2kguidelinebasal pages 1-2)
• Population-level registry data: Japan National Cancer Registry 2016–2017. (ogata2023epidemiologyofskin pages 1-2)
• Patient-level cohorts: Prospective recurrence cohort (treated tumors followed for recurrence). (chren2013tumorrecurrence5 pages 1-2)

2. Etiology

2.1 Disease causal factors

Ultraviolet (UV) radiation is consistently highlighted as a principal causal factor, with additional contributions from ionizing radiation and genetic predisposition. (schmults2023basalcellskin pages 2-4, lang2024s2kguidelinebasal pages 1-2, vallini2023signalingpathwaysand pages 2-3)

2.2 Risk factors

• UV exposure (including indoor tanning) and ionizing radiation (including prior radiotherapy) are key environmental risk factors. (schmults2023basalcellskin pages 2-4, vallini2023signalingpathwaysand pages 2-3)
• Phenotype and demographics: fair skin, red/blond hair, light eye color; older age; male sex. (schmults2023basalcellskin pages 2-4, dessinioti2023immunotherapyandits pages 1-2)
• Immunosuppression: increased risk in solid-organ transplant recipients; one 2023 review reported BCC risk elevated 6- to 16-fold vs the general population in transplant recipients in summarized literature. (vallini2023signalingpathwaysand pages 2-3)
• Genetic predisposition / genodermatoses: basal cell carcinoma syndrome (Gorlin/NBCCS), xeroderma pigmentosum (XP). (lang2024s2kguidelinebasal pages 1-2, schmults2023basalcellskin pages 2-4)
• Arsenic exposure: chronic arsenic exposure is listed as a risk factor in the German guideline and is also addressed in molecular profiling work in arsenic-exposed populations. (lang2024s2kguidelinebasal pages 1-2, alkassis2024therapeuticadvancesin pages 2-4)

2.3 Protective factors

• Photoprotection/UV avoidance: emphasized as the primary prevention strategy for non-melanoma skin cancers. (hyeraci2023systemicphotoprotectionin pages 1-2)
• Systemic photoprotection agents: A 2023 review states that among multiple oral photoprotective agents, only a few have demonstrated effectiveness in trials and have been incorporated into international guidance for NMSC prevention, including nicotinamide and retinoids. (hyeraci2023systemicphotoprotectionin pages 1-2)

2.4 Gene–environment interactions

The dominant conceptual interaction is UV-induced DNA damage superimposed on inherited or acquired susceptibility (e.g., pigmentary traits, DNA repair capacity, immune status), consistent with high UV-signature mutational patterns and known susceptibility loci; however, specific interaction effect sizes were not extractable from the retrieved texts. (vallini2023signalingpathwaysand pages 2-3, choquet2024multiancestrygenomewidemetaanalysis pages 7-7)

3. Phenotypes

3.1 Typical clinical phenotypes and presentation

BCC shows clinical heterogeneity; common subtypes include nodular and superficial BCC, with high-risk subtypes including morpheaform/sclerosing and infiltrative patterns. (alkassis2024therapeuticadvancesin pages 2-4, lang2024s2kguidelinebasal pages 1-2)

A structured phenotype/HPO mapping table is provided below.

Table: This table summarizes common clinical presentations and diagnostic features of basal cell carcinoma, with best-effort HPO mappings and key notes on distribution, aggressiveness, and metastatic rarity. It is useful for phenotype annotation and disease knowledge-base curation.

3.2 Age of onset, severity, progression

• Age of onset: German S2k guideline reports mean age of onset ~73 years (men) and 71 years (women). (lang2024s2kguidelinebasal pages 1-2)
• Course: typically slow-growing and locally invasive; metastasis is rare. (schmults2023basalcellskin pages 2-4, lang2024s2kguidelinebasal pages 1-2)

3.3 Quality-of-life impact

Guidelines emphasize that because local therapies (surgery and/or radiotherapy) are common, disfigurement and limitation of function are central morbidity concerns. (schmults2023basalcellskin pages 2-4)

4. Genetic/Molecular Information

4.1 Causal genes and key molecular drivers (current consensus)

BCC pathogenesis is strongly linked to Hedgehog (HH) pathway activation, typically via inactivation of pathway repressors (e.g., PTCH1) or activating alterations in SMO, resulting in downstream activation of GLI transcription factors. (lang2024s2kguidelinebasal pages 1-2, vallini2023signalingpathwaysand pages 2-3, alkassis2024therapeuticadvancesin pages 2-4)

A structured gene/pathway summary is provided below.

Table: This table summarizes the core molecular pathways, genes, and mechanistic features implicated in basal cell carcinoma, with frequencies and notes drawn from the retrieved evidence. It is useful for linking clinical BCC biology to driver alterations, mutational processes, and treatment resistance.

4.2 Pathogenic variants and somatic vs germline

• Somatic drivers (sporadic BCC): Hedgehog-pathway mutations are common; one 2023 advanced BCC review summarizes that ~85% of sporadic BCCs carry HH-pathway mutations (~73% PTCH loss-of-function, ~20% SMO gain-of-function, ~8% SUFU loss-of-function). (vallini2023signalingpathwaysand pages 2-3)
• Germline predisposition: Gorlin syndrome/NBCCS is linked to germline PTCH1; a 2023 review reports a small fraction of BCC is linked to Gorlin syndrome. (vallini2023signalingpathwaysand pages 2-3)

4.3 Epigenetic, chromosomal, and multi-omics

The retrieved evidence base emphasizes mutational and transcriptomic/tumor-microenvironment features rather than a consistent epigenetic signature; therefore, no specific DNA methylation/histone-modification markers are asserted here.

5. Environmental Information

5.1 Environmental and lifestyle factors

• UV radiation (sunlight and indoor tanning) and ionizing radiation are consistently cited contributors to BCC development. (schmults2023basalcellskin pages 2-4, vallini2023signalingpathwaysand pages 2-3)
• Arsenic exposure is listed as a risk factor in guideline/review evidence and is associated with NMSC molecular profiling in an arsenic-exposed population. (lang2024s2kguidelinebasal pages 1-2, alkassis2024therapeuticadvancesin pages 2-4)

5.2 Infectious agents

No specific infectious agent is established as a direct cause of BCC in the retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

1. Trigger/exposure: chronic UV exposure and/or ionizing radiation (and other modifiers such as immunosuppression). (schmults2023basalcellskin pages 2-4, vallini2023signalingpathwaysand pages 2-3)
2. DNA damage and mutation acquisition: UV-signature mutations commonly affect tumor suppressors (e.g., TP53) and Hedgehog pathway components (e.g., PTCH). (schmults2023basalcellskin pages 2-4, lang2024s2kguidelinebasal pages 1-2)
3. Pathway dysregulation: loss of PTCH-mediated repression of SMO → activation of GLI transcriptional programs → keratinocyte proliferation and tumor growth. (sol2024therapeuticapproachesfor pages 2-3, vallini2023signalingpathwaysand pages 2-3)
4. Local invasion and immune modulation: BCC can show high tumor mutational burden with an “immune excluded”/immunosuppressive microenvironment, providing a rationale for immune checkpoint blockade in advanced disease. (dessinioti2023immunotherapyandits pages 1-2, alkassis2024therapeuticadvancesin pages 2-4)

6.2 Suggested ontology mappings

• GO biological processes (examples):
• Hedgehog signaling pathway (GO:0007224)
• Regulation of cell proliferation (GO:0042127)
• DNA damage response (GO:0006974)
• Keratinocyte differentiation (GO:0030216)
• Cell Ontology (examples):
• Keratinocyte (CL:0000312)
• Epidermal basal cell (best-effort; basal keratinocyte subtype)
• Hair follicle stem cell (best-effort; stem/progenitor niche implicated in models) (nicoletti2024dysembryogeneticpathogenesisof pages 8-10)

7. Anatomical Structures Affected

7.1 Organ/tissue level

• Primary organ: skin (epidermis and adnexal structures), with most lesions on sun-exposed sites (face/head/neck; also trunk). (lang2024s2kguidelinebasal pages 1-2, sol2024therapeuticapproachesfor pages 7-8)

7.2 Cell level

• Primary affected cell type: keratinocytes/basal epidermal lineage. (sol2024therapeuticapproachesfor pages 7-8, sol2024therapeuticapproachesfor pages 2-3)
• Cell(s) of origin (model-based): evidence supports contributions from interfollicular epidermis (superficial BCC) and hair follicle stem cells (nodular BCC) in experimental contexts. (nicoletti2024dysembryogeneticpathogenesisof pages 8-10)

7.3 UBERON suggestions (best-effort)

• Skin (UBERON:0002097)
• Epidermis (UBERON:0001003)
• Hair follicle (UBERON:0002074)

8. Temporal Development

• Onset pattern: typically chronic/insidious in older adults; rapid growth and recurrence characterize the minority “difficult-to-treat” subset. (alkassis2024therapeuticadvancesin pages 1-2, lang2024s2kguidelinebasal pages 1-2)
• Progression: Most cases are “easy-to-treat”; a review-derived classification estimates ~95% are easy-to-treat, with locally advanced and metastatic disease estimated at 0.8% and 0.0028–0.55%, respectively. (sol2024therapeuticapproachesfor pages 7-8)

9. Inheritance and Population

9.1 Epidemiology (selected recent statistics)

A data-rich summary table is provided below.

Table: This table compiles high-yield epidemiology, progression, metastasis, recurrence, and systemic therapy outcome statistics for basal cell carcinoma from the gathered evidence. It is designed to support rapid comparison of population burden and clinically relevant outcome benchmarks.

Key points from recent guidelines and registry analyses: - NCCN estimates ~2 million Americans affected annually (acknowledging under-registration). (schmults2023basalcellskin pages 2-4) - German S2k guideline reports ≥200/100,000/year incidence in Germany and lifetime prevalence >10% in central/northern Europe. (lang2024s2kguidelinebasal pages 1-2) - Japan registry analysis (2016–2017) reports BCC incidence 3.63/100,000 (WHO model). (ogata2023epidemiologyofskin pages 1-2)

9.2 Genetic architecture

• Rare high-penetrance syndromes (e.g., Gorlin/NBCCS, XP) contribute to susceptibility. (lang2024s2kguidelinebasal pages 1-2, vallini2023signalingpathwaysand pages 2-3)
• Common-variant susceptibility is polygenic; a multi-ancestry GWAS meta-analysis (50,531 cases; 762,234 controls) identified 122 BCC-associated loci (36 novel). (choquet2024multiancestrygenomewidemetaanalysis pages 7-7)

10. Diagnostics

10.1 Core diagnostic approach

• Clinical exam + biopsy confirmation: NCCN recommends biopsy that includes deep reticular dermis; total body skin exam is recommended because patients are at increased risk of additional lesions and melanoma. (schmults2023basalcellskin pages 2-4)
• Imaging in selected cases: MRI preferred for suspected perineural disease; CT preferred for suspected bony involvement. (schmults2023basalcellskin pages 2-4)

10.2 Risk stratification and real-world clinical algorithms

NCCN provides operational risk stratification (low vs high risk) based on clinical and pathologic features and provides a treatment flowchart that escalates to Mohs surgery or margin-controlled approaches for high-risk tumors.

• NCCN risk stratification table and treatment algorithms (visual evidence): (schmults2023basalcellskin media 73ba3136, schmults2023basalcellskin media 96ea4de3, schmults2023basalcellskin media e102265c)

10.3 Differential diagnosis

Not systematically extracted from the retrieved evidence; in practice includes melanoma (especially for pigmented lesions), SCC, sebaceous hyperplasia, adnexal tumors, inflammatory dermatoses (for superficial BCC), and benign ulcer etiologies.

11. Outcome / Prognosis

11.1 Metastasis and advanced disease

• NCCN describes metastatic rate as <0.1%. (schmults2023basalcellskin pages 2-4)
• German guideline gives metastatic incidence estimates 0.0028%–0.55%. (lang2024s2kguidelinebasal pages 1-2)

11.2 Local control / recurrence benchmarks

Evidence for 5-year recurrence varies depending on case-mix and treatment selection. Two complementary evidence types are useful:

1) Prospective cohort (NMSC overall) with CIs: unadjusted 5-year recurrence after Mohs 2.1% (95% CI 0.6–3.5), excision 3.5% (1.8–5.2), destruction 4.9% (2.3–7.4). (chren2013tumorrecurrence5 pages 1-2)

2) Systematic-review weighted averages emphasizing BCC recurrence (commonly cited in practice): 5-year recurrence for primary BCC 1.0% after Mohs vs 10.1% after excision; recurrent BCC 5.6% after Mohs vs 17.4% after excision. (schmults2023basalcellskin pages 7-9, kauvar2015consensusfornonmelanoma pages 7-8)

12. Treatment

12.1 Treatment landscape and real-world implementation

A structured treatment table (including MAXO suggestions) is provided below.

Table: This table summarizes major basal cell carcinoma treatment options across low-risk, high-risk, and advanced disease, emphasizing real-world implementation and quantitative outcomes where available. It is useful for comparing local therapies, systemic Hedgehog inhibitors, and immunotherapy in a single evidence-linked view.

12.2 Surgery and local therapies

• Surgery is widely described as first-line for most BCCs; Mohs is prioritized for high-risk lesions to minimize recurrence and preserve tissue. (lang2024s2kguidelinebasal pages 1-2, schmults2023basalcellskin media 73ba3136)

12.3 Targeted therapy: Hedgehog pathway inhibitors (HHIs)

For locally advanced/metastatic BCC not amenable to curative surgery/radiation, vismodegib and sonidegib are first-line systemic options. High discontinuation rates are emphasized in 2023 expert review evidence: 88–92% discontinuation for vismodegib and approximately 92% for sonidegib, with about half discontinuing after ~8–12 months. (dessinioti2023immunotherapyandits pages 1-2)

12.4 Immunotherapy: PD-1 blockade

For advanced BCC after HHI failure/intolerance, cemiplimab is supported by phase 2 evidence. In the locally advanced cohort (n=84), independent central review ORR was 31% (26/84; 95% CI 21–42) with 6% complete and 25% partial responses, and median PFS 19 months (95% CI 9–not evaluable). (stratigos2021cemiplimabinlocally pages 1-1, stratigos2021cemiplimabinlocally pages 5-6)

Direct efficacy statement from the trial excerpt (data): ORR and response composition are reported numerically as above; median time to response was 4.3 months (IQR 4.2–7.2), and median duration of response was not reached, with 85% remaining in response at 12 months (Kaplan–Meier). (stratigos2021cemiplimabinlocally pages 5-6)

13. Prevention

13.1 Primary prevention (UV/radiation)

Photoprotection is emphasized as the first-choice prevention strategy for non-melanoma skin cancers given UV’s central role. (hyeraci2023systemicphotoprotectionin pages 1-2)

13.2 Chemoprevention (nicotinamide)

Evidence is mixed depending on population and pooling strategy: - Mainville et al. meta-analysis (2022): oral nicotinamide associated with reduced new skin cancers overall (rate ratio 0.50; 95% CI 0.29–0.85) and the authors report significant reduction in BCC and cSCC. (mainville2022effectofnicotinamide pages 1-2) - Tosti et al. meta-analysis (2023): pooled estimates were not statistically significant for BCC (RR 0.88; 95% CI 0.50–1.55) when combining immunocompetent and immunosuppressed cohorts; authors conclude insufficient evidence for significant reduction. (tosti2023theroleof pages 1-2) - Guideline inclusion statement (systemic photoprotection review 2023): only a few oral agents have shown efficacy in trials and have been incorporated into international guidance for NMSC prevention, including nicotinamide and retinoids. (hyeraci2023systemicphotoprotectionin pages 1-2)

13.3 Secondary prevention (screening/early detection)

• NCCN emphasizes total body skin examination and careful follow-up due to increased risk of additional keratinocyte cancers and melanoma. (schmults2023basalcellskin pages 2-4)

14. Other Species / Natural Disease

The retrieved evidence focused on mechanistic model systems rather than naturally occurring BCC in non-human populations; therefore, naturally occurring veterinary BCC epidemiology is not asserted here.

15. Model Organisms

Evidence supports several established experimental approaches: - Transgenic mouse models overexpressing HH mediators (SHH, GLI1/2, oncogenic SMO) develop BCC-like tumors. (cong2025mechanismsandtherapeutic pages 4-5) - Human keratinocyte xenograft models: engineered keratinocytes expressing SHH grafted onto nude mice generate BCC-like structures. (cong2025mechanismsandtherapeutic pages 4-5) - Lineage/cell-of-origin models: data support contributions of interfollicular epidermis vs hair follicle stem cells for different clinical subtypes; neural niche contributions are also described in mouse studies summarized in a 2024 review. (nicoletti2024dysembryogeneticpathogenesisof pages 8-10) - Ex vivo models: ex vivo skin explant culture models are noted as practical for testing therapies when primary BCC cultures are hard to maintain. (vallini2023signalingpathwaysand pages 13-14)

Notes on evidence gaps and compliance with requested identifiers

• PMIDs: Many of the retrieved recent guideline/review PDFs did not expose PMID fields in the tool outputs; therefore PMID annotation is incomplete in this run.
• ICD-11/MONDO/MeSH official IDs: Not available directly in retrieved full texts; therefore not asserted.

Key NCCN algorithm figures (visual evidence)

• NCCN risk stratification table, initial risk categorization flowchart, and high-risk treatment algorithm were extracted as images from the NCCN guideline PDF. (schmults2023basalcellskin media 73ba3136, schmults2023basalcellskin media 96ea4de3, schmults2023basalcellskin media e102265c)

References

1. (schmults2023basalcellskin pages 2-4): C. Schmults, Rachel Blitzblau, S. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy S. Bordeaux, Pei-Ling Chen, Carlo M Contreras, D. Dimaio, J. M. Donigan, J. Farma, Karthik Ghosh, Kelly Harms, Alan L Ho, J. N. Lukens, Lawrence Mark, Theresa Medina, K. Nehal, Paul Nghiem, K. Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, A. Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja S Venkat, Y. G. Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, and Sara Espinosa. Basal cell skin cancer, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21 11:1181-1203, Nov 2023. URL: https://doi.org/10.6004/jnccn.2023.0056, doi:10.6004/jnccn.2023.0056. This article has 133 citations.

2. (lang2024s2kguidelinebasal pages 1-2): Berenice M. Lang, Panagiotis Balermpas, Andrea Bauer, Andreas Blum, Thomas Dirschka, Markus Follmann, Jorge Frank, Bernhard Frerich, Klaus Fritz, Axel Hauschild, Ludwig M. Heindl, Hans‐Peter Howaldt, Stephan Ihrler, Vinodh Kakkassery, Bernhard Klumpp, Albrecht Krause‐Bergmann, Christoph Löser, Markus Meissner, Michael M. Sachse, Max Schlaak, Michael P. Schön, Lutz Tischendorf, Michael Tronnier, Dirk Vordermark, Julia Welzel, Michael Weichenthal, Susanne Wiegand, Roland Kaufmann, and Stephan Grabbe. S2k guideline basal cell carcinoma of the skin (update 2023). Journal Der Deutschen Dermatologischen Gesellschaft, 22:1697-1714, Nov 2024. URL: https://doi.org/10.1111/ddg.15566, doi:10.1111/ddg.15566. This article has 10 citations and is from a peer-reviewed journal.

3. (sol2024therapeuticapproachesfor pages 7-8): Stefano Sol, Fabiana Boncimino, Kristina Todorova, Sarah Elizabeth Waszyn, and Anna Mandinova. Therapeutic approaches for non-melanoma skin cancer: standard of care and emerging modalities. International Journal of Molecular Sciences, 25:7056, Jun 2024. URL: https://doi.org/10.3390/ijms25137056, doi:10.3390/ijms25137056. This article has 36 citations.

4. (choquet2024multiancestrygenomewidemetaanalysis pages 7-7): Hélène Choquet, Chen Jiang, Jie Yin, Yuhree Kim, Thomas J. Hoffmann, Stella Aslibekyan, Adam Auton, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, Katarzyna Bryc, Emily Bullis, Daniella Coker, Gabriel Cuellar Partida, Devika Dhamija, Sayantan Das, Sarah L. Elson, Teresa Filshtein, Kipper Fletez-Brant, Pierre Fontanillas, Will Freyman, Pooja M. Gandhi, Karl Heilbron, Barry Hicks, David A. Hinds, Ethan M. Jewett, Yunxuan Jiang, Katelyn Kukar, Keng-Han Lin, Maya Lowe, Jey McCreight, Matthew H. McIntyre, Steven J. Micheletti, Meghan E. Moreno, Joanna L. Mountain, Priyanka Nandakumar, Elizabeth S. Noblin, Jared O’Connell, Aaron A. Petrakovitz, G. David Poznik, Morgan Schumacher, Anjali J. Shastri, Janie F. Shelton, Jingchunzi Shi, Suyash Shringarpure, Vinh Tran, Joyce Y. Tung, Xin Wang, Wei Wang, Catherine H. Weldon, Peter Wilton, Alejandro Hernandez, Corinna Wong, Christophe Toukam Tchakouté, Eric Jorgenson, and Maryam M. Asgari. Multi-ancestry genome-wide meta-analysis identifies novel basal cell carcinoma loci and shared genetic effects with squamous cell carcinoma. Communications Biology, Jan 2024. URL: https://doi.org/10.1038/s42003-023-05753-7, doi:10.1038/s42003-023-05753-7. This article has 11 citations and is from a peer-reviewed journal.

5. (ogata2023epidemiologyofskin pages 1-2): Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Maiko Fujimori, Yosuke Uchitomi, Takahiro Higashi, Naoya Yamazaki, and Akira Kawai. Epidemiology of skin cancer based on japan's national cancer registry 2016–2017. Cancer Science, 114:2986-2992, Apr 2023. URL: https://doi.org/10.1111/cas.15823, doi:10.1111/cas.15823. This article has 50 citations and is from a peer-reviewed journal.

6. (vallini2023signalingpathwaysand pages 1-2): Giulia Vallini, Laura Calabrese, Costanza Canino, Emanuele Trovato, Stefano Gentileschi, Pietro Rubegni, and Linda Tognetti. Signaling pathways and therapeutic strategies in advanced basal cell carcinoma. Cells, 12:2534, Oct 2023. URL: https://doi.org/10.3390/cells12212534, doi:10.3390/cells12212534. This article has 13 citations.

7. (yang2023trendsinkeratinocyte pages 1-8): Dorothy D Yang, Kim Borsky, Chinmay Jani, Conor Crowley, Jeremy N Rodrigues, Rubeta N Matin, Dominic C Marshall, Justin D Salciccioli, Joseph Shalhoub, and Richard Goodall. Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017. The British journal of dermatology, 188 2:237-246, Oct 2023. URL: https://doi.org/10.1093/bjd/ljac064, doi:10.1093/bjd/ljac064. This article has 48 citations.

8. (chren2013tumorrecurrence5 pages 1-2): Mary-Margaret Chren, Eleni Linos, Jeanette S. Torres, Sarah E. Stuart, Rupa Parvataneni, and W. John Boscardin. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Journal of Investigative Dermatology, 133:1188-1196, May 2013. URL: https://doi.org/10.1038/jid.2012.403, doi:10.1038/jid.2012.403. This article has 250 citations and is from a highest quality peer-reviewed journal.

9. (vallini2023signalingpathwaysand pages 2-3): Giulia Vallini, Laura Calabrese, Costanza Canino, Emanuele Trovato, Stefano Gentileschi, Pietro Rubegni, and Linda Tognetti. Signaling pathways and therapeutic strategies in advanced basal cell carcinoma. Cells, 12:2534, Oct 2023. URL: https://doi.org/10.3390/cells12212534, doi:10.3390/cells12212534. This article has 13 citations.

10. (dessinioti2023immunotherapyandits pages 1-2): Clio Dessinioti and Alexander Stratigos. Immunotherapy and its timing in advanced basal cell carcinoma treatment. Dermatology Practical & Conceptual, pages e2023252, Oct 2023. URL: https://doi.org/10.5826/dpc.1304a252, doi:10.5826/dpc.1304a252. This article has 16 citations.

11. (alkassis2024therapeuticadvancesin pages 2-4): Samer Alkassis, Maya Shatta, and Deborah J. Wong. Therapeutic advances in advanced basal cell carcinoma. Cancers, 16:3075, Sep 2024. URL: https://doi.org/10.3390/cancers16173075, doi:10.3390/cancers16173075. This article has 9 citations.

12. (hyeraci2023systemicphotoprotectionin pages 1-2): Mariafrancesca Hyeraci, Elena Sofia Papanikolau, Marta Grimaldi, Francesco Ricci, Sabatino Pallotta, Rosanna Monetta, Ylenia Aura Minafò, Giovanni Di Lella, Giovanna Galdo, Damiano Abeni, Luca Fania, and Elena Dellambra. Systemic photoprotection in melanoma and non-melanoma skin cancer. Biomolecules, 13:1067, Jul 2023. URL: https://doi.org/10.3390/biom13071067, doi:10.3390/biom13071067. This article has 63 citations.

13. (schmults2023basalcellskin media 73ba3136): C. Schmults, Rachel Blitzblau, S. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy S. Bordeaux, Pei-Ling Chen, Carlo M Contreras, D. Dimaio, J. M. Donigan, J. Farma, Karthik Ghosh, Kelly Harms, Alan L Ho, J. N. Lukens, Lawrence Mark, Theresa Medina, K. Nehal, Paul Nghiem, K. Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, A. Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja S Venkat, Y. G. Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, and Sara Espinosa. Basal cell skin cancer, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21 11:1181-1203, Nov 2023. URL: https://doi.org/10.6004/jnccn.2023.0056, doi:10.6004/jnccn.2023.0056. This article has 133 citations.

14. (alkassis2024therapeuticadvancesin pages 1-2): Samer Alkassis, Maya Shatta, and Deborah J. Wong. Therapeutic advances in advanced basal cell carcinoma. Cancers, 16:3075, Sep 2024. URL: https://doi.org/10.3390/cancers16173075, doi:10.3390/cancers16173075. This article has 9 citations.

15. (alkassis2024therapeuticadvancesin pages 10-12): Samer Alkassis, Maya Shatta, and Deborah J. Wong. Therapeutic advances in advanced basal cell carcinoma. Cancers, 16:3075, Sep 2024. URL: https://doi.org/10.3390/cancers16173075, doi:10.3390/cancers16173075. This article has 9 citations.

16. (nicoletti2024dysembryogeneticpathogenesisof pages 8-10): Giovanni Nicoletti, Marco Saler, Umberto Moro, and Angela Faga. Dysembryogenetic pathogenesis of basal cell carcinoma: the evidence to date. International Journal of Molecular Sciences, 25:8452, Aug 2024. URL: https://doi.org/10.3390/ijms25158452, doi:10.3390/ijms25158452. This article has 2 citations.

17. (nicoletti2024dysembryogeneticpathogenesisof pages 11-12): Giovanni Nicoletti, Marco Saler, Umberto Moro, and Angela Faga. Dysembryogenetic pathogenesis of basal cell carcinoma: the evidence to date. International Journal of Molecular Sciences, 25:8452, Aug 2024. URL: https://doi.org/10.3390/ijms25158452, doi:10.3390/ijms25158452. This article has 2 citations.

18. (cong2025mechanismsandtherapeutic pages 4-5): Ge Cong, Xingyu Zhu, Xin Ru Chen, Hao Chen, and Wei Chong. Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer. Cell Death Discovery, Feb 2025. URL: https://doi.org/10.1038/s41420-025-02327-w, doi:10.1038/s41420-025-02327-w. This article has 41 citations and is from a peer-reviewed journal.

19. (sol2024therapeuticapproachesfor pages 2-3): Stefano Sol, Fabiana Boncimino, Kristina Todorova, Sarah Elizabeth Waszyn, and Anna Mandinova. Therapeutic approaches for non-melanoma skin cancer: standard of care and emerging modalities. International Journal of Molecular Sciences, 25:7056, Jun 2024. URL: https://doi.org/10.3390/ijms25137056, doi:10.3390/ijms25137056. This article has 36 citations.

20. (schmults2023basalcellskin pages 7-9): C. Schmults, Rachel Blitzblau, S. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy S. Bordeaux, Pei-Ling Chen, Carlo M Contreras, D. Dimaio, J. M. Donigan, J. Farma, Karthik Ghosh, Kelly Harms, Alan L Ho, J. N. Lukens, Lawrence Mark, Theresa Medina, K. Nehal, Paul Nghiem, K. Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, A. Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja S Venkat, Y. G. Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, and Sara Espinosa. Basal cell skin cancer, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21 11:1181-1203, Nov 2023. URL: https://doi.org/10.6004/jnccn.2023.0056, doi:10.6004/jnccn.2023.0056. This article has 133 citations.

21. (chren2013tumorrecurrence5 pages 3-4): Mary-Margaret Chren, Eleni Linos, Jeanette S. Torres, Sarah E. Stuart, Rupa Parvataneni, and W. John Boscardin. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Journal of Investigative Dermatology, 133:1188-1196, May 2013. URL: https://doi.org/10.1038/jid.2012.403, doi:10.1038/jid.2012.403. This article has 250 citations and is from a highest quality peer-reviewed journal.

22. (stratigos2021cemiplimabinlocally pages 5-6): Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, Nicole Basset-Seguin, Anne Lynn S Chang, Stèphane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Vladimir Jankovic, Nathalie Fiaschi, Emmanuel Okoye, Ioannis D Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M Weinreich, George D Yancopoulos, Israel Lowy, Timothy Bowler, and Matthew G Fury. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. The Lancet Oncology, 22:848-857, Jun 2021. URL: https://doi.org/10.1016/s1470-2045(21)00126-1, doi:10.1016/s1470-2045(21)00126-1. This article has 335 citations and is from a highest quality peer-reviewed journal.

23. (stratigos2021cemiplimabinlocally pages 1-1): Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, Nicole Basset-Seguin, Anne Lynn S Chang, Stèphane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Vladimir Jankovic, Nathalie Fiaschi, Emmanuel Okoye, Ioannis D Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M Weinreich, George D Yancopoulos, Israel Lowy, Timothy Bowler, and Matthew G Fury. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. The Lancet Oncology, 22:848-857, Jun 2021. URL: https://doi.org/10.1016/s1470-2045(21)00126-1, doi:10.1016/s1470-2045(21)00126-1. This article has 335 citations and is from a highest quality peer-reviewed journal.

24. (schmults2023basalcellskin media 96ea4de3): C. Schmults, Rachel Blitzblau, S. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy S. Bordeaux, Pei-Ling Chen, Carlo M Contreras, D. Dimaio, J. M. Donigan, J. Farma, Karthik Ghosh, Kelly Harms, Alan L Ho, J. N. Lukens, Lawrence Mark, Theresa Medina, K. Nehal, Paul Nghiem, K. Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, A. Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja S Venkat, Y. G. Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, and Sara Espinosa. Basal cell skin cancer, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21 11:1181-1203, Nov 2023. URL: https://doi.org/10.6004/jnccn.2023.0056, doi:10.6004/jnccn.2023.0056. This article has 133 citations.

25. (schmults2023basalcellskin media e102265c): C. Schmults, Rachel Blitzblau, S. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy S. Bordeaux, Pei-Ling Chen, Carlo M Contreras, D. Dimaio, J. M. Donigan, J. Farma, Karthik Ghosh, Kelly Harms, Alan L Ho, J. N. Lukens, Lawrence Mark, Theresa Medina, K. Nehal, Paul Nghiem, K. Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, A. Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja S Venkat, Y. G. Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, and Sara Espinosa. Basal cell skin cancer, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21 11:1181-1203, Nov 2023. URL: https://doi.org/10.6004/jnccn.2023.0056, doi:10.6004/jnccn.2023.0056. This article has 133 citations.

26. (kauvar2015consensusfornonmelanoma pages 7-8): Arielle N. B. Kauvar, Terrence Cronin, Randall Roenigk, George Hruza, and Richard Bennett. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatologic Surgery, 41:550–571, May 2015. URL: https://doi.org/10.1097/dss.0000000000000296, doi:10.1097/dss.0000000000000296. This article has 219 citations and is from a peer-reviewed journal.

27. (dessinioti2023immunotherapyandits pages 4-6): Clio Dessinioti and Alexander Stratigos. Immunotherapy and its timing in advanced basal cell carcinoma treatment. Dermatology Practical & Conceptual, pages e2023252, Oct 2023. URL: https://doi.org/10.5826/dpc.1304a252, doi:10.5826/dpc.1304a252. This article has 16 citations.

28. (mainville2022effectofnicotinamide pages 1-2): Laurence Mainville, Anne-Sophie Smilga, and Paul R. Fortin. Effect of nicotinamide in skin cancer and actinic keratoses chemoprophylaxis, and adverse effects related to nicotinamide: a systematic review and meta-analysis. Journal of Cutaneous Medicine and Surgery, 26:297-308, Feb 2022. URL: https://doi.org/10.1177/12034754221078201, doi:10.1177/12034754221078201. This article has 50 citations and is from a peer-reviewed journal.

29. (tosti2023theroleof pages 1-2): Giulio Tosti, Francesca Pepe, Patrizia Gnagnarella, Flavia Silvestri, Aurora Gaeta, Paola Queirolo, and Sara Gandini. The role of nicotinamide as chemo-preventive agent in nmscs: a systematic review and meta-analysis. Nutrients, 16:100, Dec 2023. URL: https://doi.org/10.3390/nu16010100, doi:10.3390/nu16010100. This article has 22 citations.

30. (vallini2023signalingpathwaysand pages 13-14): Giulia Vallini, Laura Calabrese, Costanza Canino, Emanuele Trovato, Stefano Gentileschi, Pietro Rubegni, and Linda Tognetti. Signaling pathways and therapeutic strategies in advanced basal cell carcinoma. Cells, 12:2534, Oct 2023. URL: https://doi.org/10.3390/cells12212534, doi:10.3390/cells12212534. This article has 13 citations.